Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KRAS | P01116 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl 2,6-Dimethoxybenzoate SCHEMBL2095636 | 0.86 | CA12 (0.65) | KMT2ACA12CA9CA1CA2 | |
| SCHEMBL1070351 | 0.86 | CA12 (0.61) | KMT2ACA12CA9CA1CA2 | |
| SCHEMBL27877492 | 0.85 | CA12 (0.59) | KMT2ACA12CA9CA1CA2 | |
| SCHEMBL184045 | 0.83 | CA12 (0.74) | KMT2ACA12CA9CA1CA2 | |
| SCHEMBL30822596 | 0.83 | CA12 (0.74) | KMT2ACA12CA9CA1CA2 | |
| SCHEMBL1957640 | 0.83 | CA9 (0.57) | KMT2ACA12CA9CA1CA2 | |
| SCHEMBL30313283 | 0.83 | CA9 (0.57) | KMT2ACA12CA9CA1CA2 | |
| SCHEMBL23442235 | 0.83 | CA12 (0.46) | KMT2ACA12CA9CA1CA2 | |
| SCHEMBL20239604 | 0.83 | LMNA (0.46) | KMT2ACA12CA9CA1CA2 | |
| SCHEMBL3372832 | 0.83 | POLB (0.53) | KMT2ACA12CA9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118561738-A | Synthesis method of 3-indolone | 南京工业大学 | 2024-08-30 | — | — | CN | disclosed |
| US-11634424-B2 | Diazaindole derivative and use thereof as CHK1 inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2023-04-25 | — | — | US | disclosed |
| US-20230017858-A1 | DIAZAINDOLE DERIVATIVE AND USE THEREOF AS CHK1 INHIBITOR | Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (CN) | 2023-01-19 | — | — | US | disclosed |
| WO-2021104461-A1 | DIAZAINDOLE DERIVATIVE AND USE THEREOF AS CHK1 INHIBITOR | 南京明德新药研发有限公司 | 2021-06-03 | — | — | WO | disclosed |
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2019-04-30 | — | — | US | disclosed |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| EP-2143724-B1 | NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL (JP) | 2013-12-11 | — | — | EP | disclosed |
| CN-101663302-B | Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes | KISSEI PHARMACEUTICAL | 2013-07-24 | — | — | CN | disclosed |
| US-8217069-B2 | Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100112090-A1 | NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD (JP) | 2010-05-06 | — | — | US | disclosed |
| CN-101663302-A | Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes | KISSEI PHARMACEUTICAL | 2010-03-03 | — | — | CN | disclosed |
| EP-2143724-A1 | NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES | Kissei Pharmaceutical Co., Ltd. (JP) | 2010-01-13 | — | — | EP | disclosed |
| EP-0779281-B1 | ISOXAZOLES | SANKYO CO (JP) | 2003-10-29 | — | — | EP | disclosed |
| US-6096771-A | ISOXAZOLE DERIVATIVES EXHIBITING EXCELLENT TYPE B AND TYPE A MONOAMINE OXIDASE INHIBITORY ACTIVITIES, THEREFORE USEFUL FOR PREVENTING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE | SANKYO COMPANY, LIMITED (JP) | 2000-08-01 | — | — | US | disclosed |
| US-5965591-A | MONOAMINE OXIDASE INHIBITOR; FOR PROPHYLAXIS AND TREATING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE | SANKYO COMPANY, LIMITED (JP) | 1999-10-12 | — | — | US | disclosed |
| CN-1162957-A | Isoxazole derivatives | SANKYO CO (JP) | 1997-10-22 | — | — | CN | disclosed |
| EP-0779281-A1 | ISOXAZOLES | SANKYO COMPANY LIMITED (JP) | 1997-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230017858-A1 | DIAZAINDOLE DERIVATIVE AND USE THEREOF AS CHK1 INHIBITOR | CHEK1, CHEK2, DDB1 | KMT2A 1197/4885CA12 4776/4885CA9 4464/4885 |
| US-11634424-B2 | Diazaindole derivative and use thereof as CHK1 inhibitor | CHEK1, CHEK2, DDB1 | KMT2A 1197/4885CA12 4776/4885CA9 4464/4885 |
| US-20100112090-A1 | NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES | NR5A1, SHBG, GNRHR | KMT2A 2609/4885CA12 1132/4885CA9 855/4885 |
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | QDPR, CYP11B2, CYP4F3 | KMT2A 4012/4885CA12 3634/4885CA9 3518/4885 |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | QDPR, CYP11B2, CYP4F3 | KMT2A 4012/4885CA12 3634/4885CA9 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.